Details
Stereochemistry | RACEMIC |
Molecular Formula | C7H15NO3 |
Molecular Weight | 161.1989 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CC(O)CC([O-])=O
InChI
InChIKey=PHIQHXFUZVPYII-UHFFFAOYSA-N
InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16924874
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16924874
L-carnitine (L-beta-hydroxy-gamma-N,N,N-trimethylaminobutyric acid) is conditionally necessary for mitochondrial transport and metabolism of long-chain fatty acids, and thus for myocardial energetic metabolism. D-carnitine is not biologically active and might interfere with proper utilization of the L isomer, and so there are claims that the racemic mixture (DL-carnitine) should be avoided. The pharmacological effects of carnitine are stereospecific: L-carnitine was effective in various animal and clinical studies, while D- and DL-carnitine was found to be ineffective or even toxic to some cells and tissues, such as muscle cells and the myocardium. DL-carnitine caused symptoms of myasthenia and cardiac arrhythmias, which disappeared after L-carnitine administration.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diasteroisomer. | 1981 May |
|
Effect of administration of carnitine on the severity of myocardial infarction induced by isoproterenol in rats. | 1986 Feb |
|
Carnitine protection against adriamycin-induced cardiomyopathy in rats. | 1986 Feb 10 |
|
Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens. | 1987 |
|
Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. | 1993 Dec |
|
Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. | 1994 Apr |
|
Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. | 1994 Jul |
|
Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy. | 1994 Oct |
|
Effect of L-carnitine supplementation on acute valproate intoxication. | 1996 Jul |
|
Lethal cardiomyopathy in epidermolysis bullosa associated with amitriptyline. | 2005 Aug |
|
Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. | 2005 Nov 1 |
|
L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. | 2006 Aug |
|
Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid. | 2006 Aug |
|
Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. | 2006 Feb |
|
Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats. | 2006 Jan 19 |
|
Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. | 2006 Mar |
|
Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. | 2006 Nov |
|
Acute renal failure due to phenazopyridine (Pyridium) overdose: case report and review of the literature. | 2006 Nov |
|
Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. | 2008 |
|
Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. | 2008 Dec 5 |
|
High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. | 2008 Jun |
|
L-carnitine mediates protection against DNA damage in lymphocytes of aged rats. | 2009 Apr |
|
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. | 2009 Apr 15 |
|
Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. | 2009 Aug 14 |
|
Organic cation/carnitine transporter OCTN3 is present in astrocytes and is up-regulated by peroxisome proliferators-activator receptor agonist. | 2009 Dec |
|
The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. | 2009 Feb |
|
Carnitine deficiency: a possible risk factor in paracetamol hepatotoxicity. | 2009 Feb |
|
Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. | 2009 Mar 21 |
|
Inactivation by omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes. | 2009 May 15 |
|
Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. | 2009 Oct |
|
Identification of a novel organic anion transporter mediating carnitine transport in mouse liver and kidney. | 2010 |
|
Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia. | 2010 Apr |
|
Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. | 2010 Apr 25 |
|
Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. | 2010 Aug 25 |
|
Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats. | 2010 Jan |
|
Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine. | 2010 Jun |
|
The plasma carnitine concentration regulates renal OCTN2 expression and carnitine transport in rats. | 2010 Jun 10 |
|
Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. | 2010 Mar 1 |
|
Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. | 2010 May |
|
Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. | 2011 Apr |
|
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. | 2011 Jun |
|
The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. | 2011 Jun 24 |
|
L-carnitine protects against nickel-induced neurotoxicity by maintaining mitochondrial function in Neuro-2a cells. | 2011 May 15 |
|
Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy. | 2011 Nov |
|
Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model. | 2012 |
|
Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models. | 2012 |
|
The protection role of heat shock protein 70 (HSP-70) in the testes of cadmium-exposed rats. | 2012 |
|
L-Carnitine rescues ketamine-induced attenuated heart rate and MAPK (ERK) activity in zebrafish embryos. | 2012 Apr |
|
Inhibition of mitochondrial carnitine/acylcarnitine transporter by H(2)O(2): molecular mechanism and possible implication in pathophysiology. | 2013 Apr 25 |
|
Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine. | 2016 Jan 22 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11742582
in rat: supplemented with dl-carnitine (DLC) (1.2 mmol . kg-1. d-1)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12937794
Using rat phrenic nerve diaphragm preparations indirectly and directly stimulated with high rate pulses, D-carnitine (30 and 60 micro M), L-carnitine (60 micro M) and DL-carnitine (60 micro M) were shown to induce tetanic fade (D-carnitine = 19.7 +/- 3.1%, N = 6; L-carnitine = 16.6 +/- 2.4%, N = 6; DL-carnitine = 14.9 +/- 2.1%, N = 6) without any reduction of maximal tetanic tension. It was shown, that tetanic fade induced by L- and DL-carnitine was antagonized by choline (60 micro M).
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
53096-4
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2047-9
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
22695-1
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2048-7
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88008-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
55200-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
17867-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
14285-1
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
34259-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2042-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
24453-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53235-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
44710-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
38481-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
14288-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88007-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
54442-9
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
780220
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
38480-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53071-7
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53233-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53234-1
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
48430-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
14287-7
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
43576-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
16556-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53112-9
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
45192-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2045-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53238-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
24448-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
CFR |
21 CFR 862.1055
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2046-1
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88024-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
22704-1
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
18363-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88011-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53072-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
30193-7
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
16555-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2043-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53054-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
43186-6
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88025-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53171-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53236-6
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
13718-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
59206-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
599517
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
24451-7
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
34257-6
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88006-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
40869-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
2044-6
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
24452-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
14286-9
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
16553-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
10561-9
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
32281-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
26788-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
32613-2
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
34258-4
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53095-6
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53053-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
10877-9
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
17866-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
88014-6
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
13719-0
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
26757-5
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
||
|
LOINC |
53162-4
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000090457
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
39547
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
4083
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
2106
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
C82599
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
SUB06134MIG
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
S7UI8SM58A
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
288
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
461-06-3
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
SUPERSEDED | |||
|
17126
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
16347
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL172513
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
D002331
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
CARNITINE
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
DTXSID3022744
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
3424
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
m3119
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
757390
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
406-76-8
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY | |||
|
S7UI8SM58A
Created by
admin on Fri Dec 15 15:12:53 GMT 2023 , Edited by admin on Fri Dec 15 15:12:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)